About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 1NCT00828594

Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma

Phase 1 Evaluate the safety and tolerability of RAD001 in combination with sorafenib in patients with advance hepatocellular cancer (HCC) and to determine the maximum tolerated dose (MTD) Phase 2 To ...

Lead sponsor: Novartis Pharmaceuticals•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Advanced liver cancer
•No previous systemic therapy for liver cancer
•Measurable disease on CT or MRI
•ECOG 1 or less
•Child-Pugh A

Exclusion Criteria

•Active bleeding during the last 30 days
•Known history of HIV seropositivity
•Any severe and/or uncontrolled medical conditions including

Related studies

MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.

NCT07607769 · Hepatocellular Carcinoma

Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma

NCT07610551 · HCC - Hepatocellular Carcinoma

RECRUITINGPhase 2

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

NCT07012798 · Hepatocellular Carcinoma (HCC)

RECRUITINGPhase 3

DEB-TACE vs cTACE in HCC After TIPS

NCT07322848 · Hepatocellular Carcinoma (HCC), TACE, and more

RECRUITINGPhase 1

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

NCT07478302 · Advanced Unresectable Hepatocellular Carcinoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 11, 2013Terms

Trial snapshot

StatusTERMINATED

PhasePHASE1

Enrollment130

Start dateDec 2008

Last updatedApr 11, 2013

Condition

Hepatocellular Carcinoma

Locations shown

City of Hope Medical Center

Duarte, California

UCLA Department of Medicine

Los Angeles, California

Duke University

Durham, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2013Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions